Recent Finacing
Recent Raise
Orphagen Pharmaceuticals screens, discovers, and develops small‑molecule ligands for orphan nuclear receptors; its oral selective RARα antagonist OR‑812 blocks α4β7 and CCR9, suppressing gut inflammation in colitis models.
